{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:02:32Z","timestamp":1778047352331,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Turku University Foundation"},{"name":"The Cancer Society of Southwest Finland"},{"name":"The Special Government Funding allocated to Turku University Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2456-1","type":"journal-article","created":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T07:13:37Z","timestamp":1467875617000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus"],"prefix":"10.1186","volume":"16","author":[{"given":"Eva-Maria","family":"Birkman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"\u00c5lgars","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minnamaija","family":"Lintunen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raija","family":"Ristam\u00e4ki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jari","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olli","family":"Carp\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,7]]},"reference":[{"key":"2456_CR1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/apm.1965.64.1.31","volume":"64","author":"P Lauren","year":"1965","unstructured":"Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31\u201349.","journal-title":"Acta Pathol Microbiol Scand"},{"key":"2456_CR2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202\u20139.","journal-title":"Nature"},{"key":"2456_CR3","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","volume":"27","author":"C Bokemeyer","year":"2009","unstructured":"Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, De Braud F, Donea S, Ludwig H, Schuch G, Stroh C, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27:663\u201371.","journal-title":"J Clin Oncol"},{"key":"2456_CR4","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","volume":"28","author":"J-Y Douillard","year":"2010","unstructured":"Douillard J-Y, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, et al. Randomized, Phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) Versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol. 2010;28:4697\u2013705.","journal-title":"J Clin Oncol"},{"key":"2456_CR5","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S1470-2045(13)70102-5","volume":"14","author":"F Lordick","year":"2013","unstructured":"Lordick F, Kang Y-K, Chung H-C, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): A randomised, open-label phase 3 trial. Lancet Oncol. 2013;14:490\u20139.","journal-title":"Lancet Oncol"},{"key":"2456_CR6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1470-2045(13)70096-2","volume":"14","author":"T Waddell","year":"2013","unstructured":"Waddell T, Chau I, Cunningham D, Gonzalez D, Frances A, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): A randomised, open-label phase 3 trial. Lancet Oncol. 2013;14:481\u20139.","journal-title":"Lancet Oncol"},{"key":"2456_CR7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/bjc.2011.223","volume":"105","author":"A \u00c5lgars","year":"2011","unstructured":"\u00c5lgars A, Lintunen M, Carp\u00e9n O, Ristam\u00e4ki R, Sundstr\u00f6m J. EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer. Br J Cancer. 2011;105:255\u201362.","journal-title":"Br J Cancer"},{"issue":"6","key":"2456_CR8","doi-asserted-by":"crossref","first-page":"e99590","DOI":"10.1371\/journal.pone.0099590","volume":"9","author":"A \u00c5lgars","year":"2014","unstructured":"\u00c5lgars A, Avoranta T, \u00d6sterlund P, Lintunen M, Sundstr\u00f6m J, Jokilehto T, Ristim\u00e4ki A, Ristam\u00e4ki R, Carp\u00e9n O. Heterogeneous EGFR gene copy number increase is common in colorectal cancer and defines response to anti-EGFR therapy. PLoS One. 2014;9(6):e99590.","journal-title":"PLoS One"},{"key":"2456_CR9","volume-title":"WHO Classification of Tumours of the Digestive System","year":"2010","unstructured":"Bosman F, Carneiro F, Hruban R, Theise N, editors. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon: IARC Press; 2010.","edition":"4"},{"key":"2456_CR10","unstructured":"Finlex Data Bank. https:\/\/www.finlex.fi\/fi\/laki\/kaannokset\/2012\/en20120688.pdf . Accessed 26 October 2015."},{"key":"2456_CR11","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","volume":"52","author":"M Hofmann","year":"2008","unstructured":"Hofmann M, Stoss O, Shi D, B\u00fcttner R, Van De Vijver M, Kim W, Ochiai A, R\u00fcschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. Histopathology. 2008;52:797\u2013805.","journal-title":"Histopathology"},{"key":"2456_CR12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"Y-J Bang","year":"2010","unstructured":"Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397.","journal-title":"Lancet"},{"key":"2456_CR13","volume-title":"Interpretation Guide. Ventana INFORM HER2 Dual ISH DNA Probe Cocktail Assay","author":"TM Grogan","year":"2010","unstructured":"Grogan TM, McElhinny AS, Loftin IR, Warren SL, Sugarman M, Miller R, Olivas-Brochu E, Roche P, Walk E, Padilla M, et al. Interpretation Guide. Ventana INFORM HER2 Dual ISH DNA Probe Cocktail Assay. 2010. http:\/\/www.uclad.com\/newsletters\/HER2_DDISH_Interpretation_Guide.pdf . Accessed 4 July 2016."},{"key":"2456_CR14","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1365-2559.2008.03021.x","volume":"52","author":"MA Kim","year":"2008","unstructured":"Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH. EGFR in gastric carcinomas: Prognostic significance of protein overexpression and high gene copy number. Histopathology. 2008;52:738\u201346.","journal-title":"Histopathology"},{"key":"2456_CR15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1136\/jclinpath-2013-201726","volume":"67","author":"C Kandel","year":"2014","unstructured":"Kandel C, Leclair F, Bou-Hanna C, Laboisse CL, Mosnier J-F. Association of HER1 amplification with poor prognosis in well differentiated gastric carcinomas. J Clin Pathol. 2014;67:307\u201312.","journal-title":"J Clin Pathol"},{"key":"2456_CR16","doi-asserted-by":"crossref","unstructured":"Nagatsuma AK, Aizawa M, Kuwata T, Doi T, Ohtsu A, Fujii H, Ochiai A. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. Gastric Cancer. 2015;18:227\u201338.","DOI":"10.1007\/s10120-014-0360-4"},{"key":"2456_CR17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/annonc\/mdi064","volume":"16","author":"M Tanner","year":"2005","unstructured":"Tanner M, Hollm\u00e9n M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, et al. Amplification of HER-2 in gastric carcinoma: Association with Topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16:273\u20138.","journal-title":"Ann Oncol"},{"key":"2456_CR18","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/ijc.10257","volume":"98","author":"T Takehana","year":"2002","unstructured":"Takehana T, Kunitomo K, Kono K, Kitahara F, Iizuka H, Matsumoto Y, Fujino MA, Ooi A. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer. 2002;98:833\u20137.","journal-title":"Int J Cancer"},{"key":"2456_CR19","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","volume":"19","author":"C Gravalos","year":"2008","unstructured":"Gravalos C, Jimeno A. HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523\u20139.","journal-title":"Ann Oncol"},{"key":"2456_CR20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nm.3850","volume":"21","author":"R Cristescu","year":"2015","unstructured":"Cristescu R, Nebozhyn M, Kim K-M, Ting J, Wong S, Liu J, Yue Y, Wang J, Yu K, Ye X, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21:449\u201356.","journal-title":"Nat Med"},{"key":"2456_CR21","volume-title":"L. Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer","author":"Kuhnil Pharmaceutical Co.","year":"2013","unstructured":"Kuhnil Pharmaceutical Co. L. Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer. Bethesda: National Library of Medicine; 2013. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01813253 . Accessed 08 Oct 2015."},{"key":"2456_CR22","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1038\/srep02992","volume":"3","author":"L Zhang","year":"2013","unstructured":"Zhang L, Yang J, Cai J, Song X, Deng J, Huang X, Chen D, Yang M, Wery J-P, Li S, et al. A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy. Sci Rep. 2013;3:2992.","journal-title":"Sci Rep"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2456-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T20:37:18Z","timestamp":1568147838000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2456-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,7]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2456"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2456-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,7]]},"article-number":"406"}}